A recent study reveals that individuals who stop using blockbuster GLP-1 drugs like semaglutide or tirzepatide can put back on reduced body mass at a significantly accelerated pace than those who end conventional lifestyle programs.
Findings released in a prominent medical journal shows that while obese people can lose about a fifth of their total mass while undergoing treatment, the weight returns at an estimated rate of nearly a kilo each month after stopping.
"Users purchasing these treatments should be cognizant of the potential of quick weight regain when the medication is stopped," cautioned researcher Dr. Susan Jebb.
This pace of recovery means a reversion to pre-treatment mass within about 18 months.
Weighing Therapies
The analysis, which examined 37 of trials involving thousands of participants, compared the results of GLP-1 agonists with older methods.
Scientists emphasize that people who shed pounds through lifestyle changes alone generally have a more gradual weight regain—around 100 grams monthly—once they finish.
Explaining the Rapid Regain
Nutrition scientists believe the mechanism of the drugs accounts for the amplified weight return.
These medications copy a body's own chemical called GLP-1, which controls appetite.
"Sustained high doses of the hormone levels several times higher than the body's typical production might result in the body to produce less of its endogenous hormone, and could reduce responsiveness to its effects," explained Dr. Adam Collins, a dietetics expert.
"Withdrawal of this hormone supplement leads to appetite is uncontrolled, making overeating far more likely."
A Lifelong Disease?
Health authorities suggest the jabs for individuals with weight-linked medical conditions, accompanied by recommended lifestyle changes.
Professionals say that, considering the likelihood of weight regain, the therapy might need to be long-term.
This opinion is echoed by drug manufacturers, who note that the findings "underscore the long-term character of obesity," comparing it to managing diseases like diabetes.
Patient Testimonies
Individuals who have come off the medication describe a intense return of appetite.
"I experienced a switch that goes on and you become starving," described an individual.
This challenge is exacerbated if users have not established lasting dietary or behavioural modifications during therapy.
Significant Interest
Figures suggest that a significant number of adults in the UK have used these injections in the past year, with desire being substantial.
- Use is more common among females than males.
- The 40s and 50s demographic shows the highest usage rates.
- A large proportion obtain the drugs through private healthcare rather than public health services.
Finally, clinicians stress that while GLP-1 drugs are powerful tools for weight loss, they are not a magic cure and lasting health benefits hinges on integrated lifestyle support.
